Janux Therapeutics, Inc. (JANX) Tops Q3 EPS by 23c

Janux Therapeutics, Inc. (NASDAQ: JANX) reported Q3 EPS of ($0.39), $0.23 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $10 million versus the consensus estimate of $2.88 million.

For earnings history and earnings-related data on Janux Therapeutics, Inc. (JANX) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Freedom Broker Starts Autoliv, Inc. (ALV) at Buy
• Boeing and Bell Boeing receive defense contracts totaling $56.4M